HCW Biologics prices $1.5 million follow-on offering at $0.6055 per unit Feb 18, 2026 04:33AM
HCW Biologics raises $4 million through warrant exercise agreement Nov 19, 2025 08:30AM
HCW Biologics begins first human trial of HCW9302 for autoimmune disease Nov 18, 2025 07:25AM
HCW Biologics (HCWB) Misses Q3 EPS by 202c Nov 14, 2025 05:33PM
Wugen raises $115 million in equity financing led by Fidelity Sep 18, 2025 09:16AM


Sep 9, 2025 08:01AM HCW Biologics reports positive primate study results for T-cell engager
Aug 25, 2025 08:23AM HCW Biologics develops pembrolizumab-based cancer treatment
Aug 20, 2025 05:49AM HCW Biologics (HCWB) Misses Q2 EPS by 679c
Jun 27, 2025 07:50AM HCW Biologics (HCWB) to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors
Jun 26, 2025 07:56AM HCW Biologics (HCWB) Regains Nasdaq Compliance
Jun 4, 2025 08:21AM HCW Biologics (HCWB) Completes Deliverable and Solidifies License Agreement with WY Biotech
May 16, 2025 04:25PM HCW Biologics Inc. (HCWB) Reports Q1 Loss of $0.05
May 13, 2025 08:31AM HCW Biologics (HCWB) Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization
Apr 1, 2025 04:36PM HCW Biologics (HCWB) announces 1-for-40 reverse stock split to regain Nasdaq compliance
Mar 6, 2025 06:57AM HCW Biologics (HCWB) Granted Nasdaq Extension to Regain Compliance
Feb 3, 2025 07:16AM HCW Biologics (HCWB) Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates
Nov 18, 2024 07:08AM HCW Biologics (HCWB) and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate